Orion is a clinical stage company leveraging a proprietary technology platform to develop next generation therapeutics for effectively targeting G Protein-Coupled Receptors (GPCRs). Orion’s platform enables effectively targeting previously undruggable complex GPCRs. Our pipeline includes 3 next generation therapeutics for cancer including our lead candidate - OB-002 – which is a first-in-class cancer immunotherapy with best-in-class potency.
Company Details
- Employees
- 21
- Founded
- 2017
- Address
- 343 Preston Street, 11th Floor,poland
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- orionbiotechnology.com
- Keywords
- cell receptor pharmacology, chemokines, chemokine analogues, technology commercialization, clincal operations, immunology, microbicides, translational medicine.
- HQ
- Ottawa, On
Orion Biotechnology Questions
Orion Biotechnology's website is orionbiotechnology.com
Orion Biotechnology's LinkedIn profile is https://ca.linkedin.com/company/orion-biotechnology
Orion Biotechnology has
21 employees.
View email and phone details for 21
employees at Orion Biotechnology.
Orion Biotechnology's industry is
Pharmaceutical Manufacturing
Orion Biotechnology's top competitors are
Genomadix,
Biotecanada,
Virica Biotech,
Dna Genotek,
Spiderwort Biotechnologies Inc.,
Novel Bio,
Aptamers- Neoventures Biotechnology Inc.,
Lupos (Canada) Biotechnology Inc.,
Generex Biotechnology Corporation,
Intrinsik Corp. - Pharmaceuticals & Biotechnology.
Orion Biotechnology's categories are Pharmaceutical Manufacturing
Orion Biotechnology's founding year is 2017
